2.49
-0.08 (-3.11%)
| Previous Close | 2.57 |
| Open | 2.58 |
| Volume | 382,268 |
| Avg. Volume (3M) | 629,903 |
| Market Cap | 182,111,088 |
| Price / Sales | 1.42 |
| Price / Book | 0.480 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -19.77% |
| Operating Margin (TTM) | -61.02% |
| Diluted EPS (TTM) | -0.420 |
| Quarterly Revenue Growth (YOY) | -44.70% |
| Total Debt/Equity (MRQ) | 3.58% |
| Current Ratio (MRQ) | 12.34 |
| Operating Cash Flow (TTM) | 27.37 M |
| Levered Free Cash Flow (TTM) | 12.04 M |
| Return on Assets (TTM) | -4.80% |
| Return on Equity (TTM) | -7.77% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Bullish | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | OraSure Technologies, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 1.30 |
|
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 4.83% |
| % Held by Institutions | 89.49% |
| 52 Weeks Range | ||
| Median | 3.00 (20.48%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stephens & Co. | 12 Nov 2025 | 3.00 (20.48%) | Hold | 2.47 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| KENNY JOHN P. | 2.46 | - | 10,286 | 25,304 |
| Aggregate Net Quantity | 10,286 | |||
| Aggregate Net Value ($) | 25,304 | |||
| Aggregate Avg. Buy ($) | 2.46 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KENNY JOHN P. | Director | 17 Dec 2025 | Acquired (+) | 10,286 | 2.46 | 25,304 |
| Date | Type | Details |
|---|---|---|
| 17 Dec 2025 | Announcement | OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates |
| 17 Dec 2025 | Announcement | Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors |
| 17 Nov 2025 | Announcement | OraSure to Participate in Upcoming Investor Conference |
| 05 Nov 2025 | Announcement | OraSure Announces Third Quarter 2025 Financial Results |
| 29 Oct 2025 | Announcement | OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th |
| 28 Oct 2025 | Announcement | OraSure Technologies Appoints Steven K. Boyd to its Board of Directors |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |